Identification of single nucleotide non-coding driver mutations in cancer
Gan, Kok A.
Pro, Sebastian Carrasco
Sewell, Jared A.
Fuxman Bass, Juan I.
MetadataShow full item record
Citation (published version)Kok A Gan, Sebastian Carrasco Pro, Jared A Sewell, Juan I Fuxman Bass. 2018. "Identification of Single Nucleotide Non-coding Driver Mutations in Cancer." FRONTIERS IN GENETICS, Volume 9, pp. ? - ? (10). https://doi.org/10.3389/fgene.2018.00016
Recent whole-genome sequencing studies have identified millions of somatic variants present in tumor samples. Most of these variants reside in non-coding regions of the genome potentially affecting transcriptional and post-transcriptional gene regulation. Although a few hallmark examples of driver mutations in non-coding regions have been reported, the functional role of the vast majority of somatic non-coding variants remains to be determined. This is because the few driver variants in each sample must be distinguished from the thousands of passenger variants and because the logic of regulatory element function has not yet been fully elucidated. Thus, variants prioritized based on mutational burden and location within regulatory elements need to be validated experimentally. This is generally achieved by combining assays that measure physical binding, such as chromatin immunoprecipitation, with those that determine regulatory activity, such as luciferase reporter assays. Here, we present an overview of in silico approaches used to prioritize somatic non-coding variants and the experimental methods used for functional validation and characterization.
RightsAttribution 4.0 International
Showing items related by title, author, creator and subject.
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation Yamada, Teppei; Azuma, Koichi; Muta, Emi; Kim, Jintaek; Sugawara, Shunichi; Zhang, Guang Lan; Matsueda, Satoko; Kasama-Kawaguchi, Yuri; Yamashita, Yuichi; Yamashita, Takuto; Nishio, Kazuto; Itoh, Kyogo; Hoshino, Tomoaki; Sasada, Tetsuro (Public Library of Science, 2013)Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, has achieved high clinical response rates in patients with non-small cell lung cancers (NSCLCs). ...
Cho, Michael H.; Klanderman, Barbara J.; Litonjua, Augusto A.; Sparrow, David; Silverman, Edwin K.; Raby, Benjamin A. (BioMed Central, 2008-12-30)BACKGROUND: Rare loss-of-function folliculin (FLCN) mutations are the genetic cause of Birt-Hogg-Dubé syndrome, a monogenic disorder characterized by spontaneous pneumothorax, fibrofolliculomas, and kidney tumors. ...
The Gly2019Ser Mutation in LRRK2 Is not Fully Penetrant in Familial Parkinson's Disease: The GenePD Study Latourelle, Jeanne C.; Sun, Mei; Lew, Mark F.; Suchowersky, Oksana; Klein, Christine; Golbe, Lawrence I.; Mark, Margery H.; Growdon, John H.; Wooten, G. Frederick; Watts, Ray L.; Guttman, Mark; Racette, Brad A.; Perlmutter, Joel S.; Ahmed, Anwar; Shill, Holly A.; Singer, Carlos; Goldwurm, Stefano; Pezzoli, Gianni; Zini, Michela; Saint-Hilaire, Marie H.; Hendricks, Audrey E.; Williamson, Sally; Nagle, Michael W.; Wilk, Jemma B.; Massood, Tiffany; Huskey, Karen W.; Laramie, Jason M.; DeStefano, Anita L.; Baker, Kenneth B.; Itin, Ilia; Litvan, Irene; Nicholson, Garth; Corbett, Alastair; Nance, Martha; Drasby, Edward; Isaacson, Stuart; Burn, David J.; Chinnery, Patrick F.; Pramstaller, Peter P.; Al-hinti, Jomana; Moller, Anette T.; Ostergaard, Karen; Sherman, Scott J.; Roxburgh, Richard; Snow, Barry; Slevin, John T.; Cambi, Franca; Gusella, James F.; Myers, Richard H. (BioMed Central, 2008-11-5)BACKGROUND: We report age-dependent penetrance estimates for leucine-rich repeat kinase 2 (LRRK2)-related Parkinson's disease (PD) in a large sample of familial PD. The most frequently seen LRRK2 mutation, Gly2019Ser ...